Skip to content

BECOME CHILDREN OF HOLDERS Corpus Callosum Agenesis Screened IN PERIOD Antenatal

BECOME CHILDREN OF HOLDERS Corpus Callosum Agenesis Screened IN PERIOD Antenatal

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02826824
Enrollment
60
Registered
2016-07-11
Start date
2016-07-31
Completion date
2017-09-30
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corpus Callosum Agenesis

Keywords

corpus callosum agenesis, agenesis, corpus callosum

Brief summary

The corpus callosum agenesis is an interesting malformation between 0.05% and 1.5% of the general population. This malformation is mostly diagnosed prenatally by ultrasound, usually at 22 weeks of gestation, and the use of prenatal advice is routinely offered to the couple. Several studies in recent years have helped to define the determinants of prognosis for the unborn child suffers from agenesis of the corpus callosum, whether total or partial. These, mainly retrospective, demonstrated that the isolated nature of the deformity (defined as no other brain malformations and brain extra, absence of abnormal karyotype, maternal poisoning or viral seroconversion when pregnancy) is associated with favorable developments in terms of psychomotor development in 80% of cases Similar results were also found in prospective studies, while the associated nature of the defect seems most heavily encumber the prognosis as other malformation or syndrome associated with agenesis of the corpus callosum Although these recent data have already significantly influence prenatal counseling and outcome of pregnancy, questions about the future of the child carrying a prenatal diagnosis of agenesis of the corpus callosum are still valid.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 13 Years
Healthy volunteers
No

Inclusion criteria

* Children born between January 2000 and January 2013 carrying a corpus callosum agenesis detected prenatally via the multidisciplinary center for prenatal diagnosis (CPDPN) of the Alsace-Lorraine region, * Children whose holders of parental authority does not oppose the use of clinical data from their child for research purposes

Exclusion criteria

* Children whose holders of parental authority are opposed to the use of clinical data from their child for research purposes

Design outcomes

Primary

MeasureTime frame
questionnairesince January 2000 to january 2016

Countries

France

Contacts

Primary ContactVincent LAUGEL, MD, PhD
Vincent.LAUGEL@chru-strasbourg.fr33 (0)3.88.12.84.98
Backup ContactEléonore FEUGEAS, MD
Eleonore.feugeas@chru-strasbourg.fr33 (0)3.88.12.84.98

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026